

Herbert Lepor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6147194/publications.pdf>

Version: 2024-02-01

196
papers

14,447
citations

23567

58
h-index

19749

117
g-index

203
all docs

203
docs citations

203
times ranked

7483
citing authors

#	ARTICLE	IF	CITATIONS
1	Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 114-119.	3.9	13
2	MRI predicts prostatic urethral involvement in men undergoing radical prostatectomy: implications for cryo-ablation of localized prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 3309-3314.	2.2	0
3	Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort: How Many Clinically Significant Prostate Cancers are Missed?. <i>Journal of Urology</i> , 2021, 205, 740-747.	0.4	13
4	Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration. <i>Cancer</i> , 2021, 127, 3985-3990.	4.1	8
5	5-Year Outcomes Following Focal Laser Ablation of Prostate Cancer. <i>Urology</i> , 2021, 155, 124-129.	1.0	12
6	AUTHOR REPLY. <i>Urology</i> , 2021, 155, 129.	1.0	0
7	Copolymerization of single-cell nucleic acids into balls of acrylamide gel. <i>Genome Research</i> , 2020, 30, 49-61.	5.5	9
8	Oncological control following partial gland ablation for intermediate-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 671-677.	1.6	8
9	Exploring Variation in the Use of Conservative Management for Low-risk Prostate Cancer in the Veterans Affairs Healthcare System. <i>European Urology</i> , 2020, 77, 683-686.	1.9	16
10	Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer. <i>Urology</i> , 2020, 141, 119-124.	1.0	16
11	Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 21727-21731.	7.1	151
12	EDITORIAL COMMENT. <i>Urology</i> , 2019, 133, 179.	1.0	0
13	Prostate Cancer Screening and Management in Solid Organ Transplant Candidates and Recipients. <i>Reviews in Urology</i> , 2019, 21, 85-92.	0.9	3
14	E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1560-E1569.	7.1	235
15	The Use of Magnetic Resonance Imaging to Predict Oncological Control Among Candidates for Focal Ablation of Prostate Cancer. <i>Urology</i> , 2018, 112, 121-125.	1.0	18
16	Informational needs during active surveillance for prostate cancer: A qualitative study. <i>Patient Education and Counseling</i> , 2018, 101, 241-247.	2.2	15
17	Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 348-358.	0.9	24
18	Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings. <i>Urology</i> , 2018, 112, 112-120.	1.0	36

#	ARTICLE	IF	CITATIONS
19	Multiparametric magnetic resonance imaging identifies significant apical prostate cancers. <i>BJU International</i> , 2018, 121, 239-243.	2.5	13
20	Optimizing patient selection for focal therapyâ€”mapping and ablating the index lesion. <i>Translational Andrology and Urology</i> , 2018, 7, S519-S525.	1.4	3
21	Health state utilities among contemporary prostate cancer patients on active surveillance. <i>Translational Andrology and Urology</i> , 2018, 7, 197-202.	1.4	3
22	Uroplakins play conserved roles in egg fertilization and acquired additional urothelial functions during mammalian divergence. <i>Molecular Biology of the Cell</i> , 2018, 29, 3128-3143.	2.1	11
23	The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years. <i>Journal of Urology</i> , 2018, 200, 1022-1029.	0.4	64
24	Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2231.	7.4	59
25	Long-Term Continence Outcomes in Men Undergoing Radical Prostatectomy: A Prospective 15-Year Longitudinal Study. <i>Journal of Urology</i> , 2018, 200, 626-632.	0.4	6
26	Long-term Natural History of Lower Urinary Tract Symptoms Following Radical Retropubic Prostatectomy: A Prospective 15-Year Longitudinal Study. <i>Urology</i> , 2018, 120, 167-172.	1.0	0
27	Two-year Outcomes Following Focal Laser Ablation of Localized Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 129-133.	5.4	21
28	Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6152-E6161.	7.1	88
29	Focal Ablation of Prostate Cancer. <i>Reviews in Urology</i> , 2018, 20, 145-157.	0.9	7
30	Focal Ablation of Prostate Cancer. <i>Reviews in Urology</i> , 2018, 20, 107-111.	0.9	0
31	Surgical Treatment of Prostate Carcinoma. <i>Journal of Urology</i> , 2017, 197, S41-S42.	0.4	3
32	Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy. <i>BJU International</i> , 2017, 120, 505-510.	2.5	3
33	Benign Prostatic Obstruction Relief in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement Undergoing Endoscopic Surgical Procedures or Therapy with Alpha-Blockers: A Review of Urodynamic Studies. <i>Advances in Therapy</i> , 2017, 34, 773-783.	2.9	19
34	The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. <i>Urology</i> , 2017, 102, 178-182.	1.0	54
35	Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. <i>European Urology</i> , 2017, 72, 899-907.	1.9	23
36	Editorial Comment. <i>Journal of Urology</i> , 2017, 198, 343-344.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. International Journal of Radiation Oncology Biology Physics, 2017, 97, 511-515.	0.8	9
38	Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. Urology, 2017, 99, 174-179.	1.0	41
39	New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. European Urology, 2017, 71, 17-34.	1.9	232
40	Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition. Abdominal Radiology, 2017, 42, 290-297.	2.1	7
41	Qualitative study on decision-making by prostate cancer physicians during active surveillance. BJU International, 2017, 120, 32-39.	2.5	29
42	Multi-parametric MRI imaging of the prostate—implications for focal therapy. Translational Andrology and Urology, 2017, 6, 453-463.	1.4	19
43	Magnetic resonance imaging in prostate cancer. Translational Andrology and Urology, 2017, 6, 343-344.	1.4	3
44	Likert score 3 prostate lesions: Association between whole-lesion ADC metrics and pathologic findings at MRI/ultrasound fusion targeted biopsy. Journal of Magnetic Resonance Imaging, 2016, 43, 325-332.	3.4	25
45	Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results. BJU International, 2016, 118, 515-520.	2.5	109
46	Editorial Comment. Urology, 2016, 91, 116-117.	1.0	0
47	Editorial Comment. Urology, 2016, 93, 74.	1.0	0
48	Testosterone Deficiency and the Prostate. Urologic Clinics of North America, 2016, 43, 203-208.	1.8	9
49	Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia. Urologic Clinics of North America, 2016, 43, 311-323.	1.8	37
50	Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy. Journal of Endourology, 2016, 30, 1291-1295.	2.1	4
51	The Challenge for Urologists Is to Screen, Detect, and Treat Prostate Cancer—Smarter? Will Ablative Technology Result in Smarter Treatment?. European Urology, 2016, 70, 456-457.	1.9	0
52	Size-adjusted Quantitative Gleason Score as a Predictor of Biochemical Recurrence after Radical Prostatectomy. European Urology, 2016, 70, 248-253.	1.9	17
53	A prospective comparative analysis of the accuracy of HistoScanning and multiparametric magnetic resonance imaging in the localization of prostate cancer among men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 3.e1-3.e8.	1.6	8
54	How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States. Journal of Urology, 2016, 196, 721-726.	0.4	81

#	ARTICLE	IF	CITATIONS
55	Is Targeted Therapy of Prostate Cancer Ready for Prime Time?. <i>European Urology</i> , 2016, 69, 221-222.	1.9	2
56	Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusionâ€”targeted Prostate Biopsy Outcomes. <i>European Urology</i> , 2016, 69, 512-517.	1.9	163
57	Twitter response to the United States Preventive Services Task Force recommendations against screening with prostateâ€”specific antigen. <i>BJU International</i> , 2015, 116, 65-71.	2.5	39
58	Long-term Satisfaction After Open Radical Prostatectomy. <i>Urology</i> , 2015, 85, 1130-1136.	1.0	3
59	Prebiopsy MRI and MRI-ultrasound Fusionâ€”targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. <i>Urology</i> , 2015, 86, 1192-1199.	1.0	71
60	10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era. <i>Urology</i> , 2015, 86, 783-789.	1.0	12
61	Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy. <i>Journal of Urology</i> , 2015, 194, 1234-1240.	0.4	8
62	Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer. <i>European Urology</i> , 2015, 68, 924-926.	1.9	73
63	Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. <i>Journal of Urology</i> , 2015, 194, 1601-1606.	0.4	87
64	Reply. <i>Urology</i> , 2015, 86, 788-789.	1.0	0
65	Cigarette side-stream smoke lung and bladder carcinogenesis: inducing mutagenic acrolein-DNA adducts, inhibiting DNA repair and enhancing anchorage-independent-growth cell transformation. <i>Oncotarget</i> , 2015, 6, 33226-33236.	1.8	46
66	Using the 4Kscore Test and Magnetic Resonance Imaging Results to Avoid Unnecessary Prostate Biopsy. <i>Reviews in Urology</i> , 2015, 17, 1-2.	0.9	2
67	The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. <i>Reviews in Urology</i> , 2015, 17, 140-9.	0.9	17
68	Juxta-adrenal Ancient Schwannoma: A Rare Retroperitoneal Tumor. <i>Reviews in Urology</i> , 2015, 17, 97-101.	0.9	3
69	Editorial Comment. <i>Urology</i> , 2014, 84, 1458.	1.0	0
70	Ten-year Outcomes of Sexual Function After Radical Prostatectomy: Results of a Prospective Longitudinal Study. <i>European Urology</i> , 2014, 65, 58-65.	1.9	70
71	Long-term Continence Outcomes in Men Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. <i>European Urology</i> , 2014, 65, 52-57.	1.9	56
72	Identifying quantitative in vivo multi-parametric MRI features for treatment related changes after laser interstitial thermal therapy of prostate cancer. <i>Neurocomputing</i> , 2014, 144, 13-23.	5.9	17

#	ARTICLE	IF	CITATIONS
73	Radical Prostatectomy Improves and Prevents Age Dependent Progression of Lower Urinary Tract Symptoms. <i>Journal of Urology</i> , 2014, 191, 412-417.	0.4	31
74	A Prospective, Blinded Comparison of Magnetic Resonance (MR) Imagingâ€“Ultrasound Fusion and Visual Estimation in the Performance of MR-targeted Prostate Biopsy: The PROFUS Trial. <i>European Urology</i> , 2014, 66, 343-351.	1.9	344
75	Optimization of Prostate Biopsy: the Role of Magnetic Resonance Imaging Targeted Biopsy in Detection, Localization and Risk Assessment. <i>Journal of Urology</i> , 2014, 192, 648-658.	0.4	156
76	Adoption of an Integrated Radiology Reading Room Within a Urologic Oncology Clinic: Initial Experience in Facilitating Clinician Consultations. <i>Journal of the American College of Radiology</i> , 2014, 11, 496-500.	1.8	20
77	Novel role of X-linked inhibitor of apoptosis protein (XIAP) in bladder cancer cell invasion and prediction of disease progression.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15504-e15504.	1.6	1
78	Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. <i>Reviews in Urology</i> , 2014, 16, 55-66.	0.9	47
79	Combination Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms: 1 + 1 Does Not Equal 2. <i>European Urology</i> , 2013, 64, 244-246.	1.9	2
80	Editorial Comment. <i>Urology</i> , 2013, 82, 1353-1354.	1.0	0
81	80 RADICAL PROSTATECTOMY (RP) PREVENTS AGE-DEPENDENT PROGRESSION OF LOWER URINARY TRACT SYMPTOMS (LUTS). <i>Journal of Urology</i> , 2013, 189, .	0.4	1
82	Gleason 6 Prostate Tumors Diagnosed in the PSA Era Do Not Demonstrate the Capacity for Metastatic Spread at the Time of Radical Prostatectomy. <i>Urology</i> , 2013, 82, 148-153.	1.0	32
83	Quantitative evaluation of treatment related changes on multi-parametric MRI after laser interstitial thermal therapy of prostate cancer. <i>Proceedings of SPIE</i> , 2013, 8671, 86711F.	0.8	6
84	Short-, Intermediate-, and Long-term Quality of Life Outcomes Following Radical Prostatectomy for Clinically Localized Prostate Cancer. <i>Reviews in Urology</i> , 2013, 15, 161-77.	0.9	23
85	Î±-Blockers for benign prostatic hyperplasia. <i>Current Opinion in Urology</i> , 2012, 22, 7-15.	1.8	83
86	Radical Prostatectomy for Long-Term Functional and Oncologic Outcomes. <i>European Urology</i> , 2012, 61, 676-678.	1.9	0
87	The effect of surgical intervention for stress urinary incontinence (UI) on postâ€“prostatectomy UI during sexual activity. <i>BJU International</i> , 2012, 109, 1208-1212.	2.5	37
88	Clinical evaluation of a novel method for the measurement of prostateâ€“specific antigen, AccuPSATM, as a predictor of 5â€“year biochemical recurrenceâ€“free survival after radical prostatectomy: results of a pilot study. <i>BJU International</i> , 2012, 109, 1770-1775.	2.5	17
89	Blood loss during radical prostatectomy: impact on clinical, oncological and functional outcomes and complication rates. <i>BJU International</i> , 2012, 110, 69-75.	2.5	18
90	Comparison of healthâ€“related qualityâ€“ofâ€“life outcomes for Africanâ€“American and Caucasianâ€“American men after radical prostatectomy. <i>BJU International</i> , 2012, 110, 1129-1133.	2.5	11

#	ARTICLE	IF	CITATIONS
91	Post-Prostatectomy Incontinence During Sexual Activity: A Single Center Prevalence Study. <i>Journal of Urology</i> , 2011, 186, 982-985.	0.4	54
92	The short-term use of erythropoietin-stimulating agents: impact on the biochemical recurrence of prostate cancer. <i>BJU International</i> , 2011, 108, 1582-1587.	2.5	3
93	Three-Year Postoperative Ultrasensitive Prostate-Specific Antigen Following Open Radical Retropubic Prostatectomy Is a Predictor for Delayed Biochemical Recurrence. <i>European Urology</i> , 2011, 60, 548-553.	1.9	17
94	Fifth-Generation Digital Immunoassay for Prostate-Specific Antigen by Single Molecule Array Technology. <i>Clinical Chemistry</i> , 2011, 57, 1712-1721.	3.2	55
95	Medical treatment of benign prostatic hyperplasia. <i>Reviews in Urology</i> , 2011, 13, 20-33.	0.9	28
96	Sildenafil for the Treatment of Benign Prostatic Hyperplasia: Pharmacology and Cardiovascular Tolerability. <i>Pharmacotherapy</i> , 2010, 30, 1303-1312.	2.6	26
97	Patient Centered Outcomes in Prostate Cancer Treatment: Predictors of Satisfaction Up to 2 Years After Open Radical Retropubic Prostatectomy. <i>Journal of Urology</i> , 2010, 184, 1977-1981.	0.4	33
98	The Preoperative Use of Erythropoietin Stimulating Proteins Prior to Radical Prostatectomy Is Not Associated With Increased Cardiovascular or Thromboembolic Morbidity or Mortality. <i>Urology</i> , 2010, 75, 1424-1428.	1.0	7
99	Editorial Comment. <i>Urology</i> , 2010, 76, 933.	1.0	0
100	Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy. <i>Urology</i> , 2010, 76, 689-692.	1.0	84
101	Neurovascular bundle resection: Does it improve the margins?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 215-218.	1.6	15
102	Can contemporary transrectal prostate biopsy accurately select candidates for hemiablatable focal therapy of prostate cancer?. <i>BJU International</i> , 2009, 104, 195-199.	2.5	46
103	Site of positive surgical margins influences biochemical recurrence after radical prostatectomy. <i>BJU International</i> , 2009, 104, 1610-1614.	2.5	69
104	Does Benign Prostatic Tissue Contribute to Measurable PSA Levels After Radical Prostatectomy?. <i>Urology</i> , 2009, 74, 167-170.	1.0	35
105	Factors Predicting Preservation of Erectile Function in Men Undergoing Open Radical Retropubic Prostatectomy. <i>Journal of Urology</i> , 2009, 181, 1817-1822.	0.4	66
106	Changes in Continence and Erectile Function Between 2 and 4 Years After Radical Prostatectomy. <i>Journal of Urology</i> , 2009, 181, 731-735.	0.4	71
107	Status of radical prostatectomy in 2009: is there medical evidence to justify the robotic approach?. <i>Reviews in Urology</i> , 2009, 11, 61-70.	0.9	35
108	Does a nerve-sparing technique or potency affect continence after open radical retropubic prostatectomy?. <i>BJU International</i> , 2008, 102, 1581-1584.	2.5	67

#	ARTICLE	IF	CITATIONS
109	Prostate-Specific Antigen Doubling Time Is a Reliable Predictor of Imageable Metastases in Men with Biochemical Recurrence After Radical Retropubic Prostatectomy. <i>Urology</i> , 2008, 71, 501-505.	1.0	15
110	Does Open Radical Retropubic Prostatectomy Decrease the Risk of Acute Urinary Retention?. <i>Urology</i> , 2008, 72, 821-824.	1.0	4
111	Transabdominal Sonocystography: A Novel Technique to Assess Vesicourethral Extravasation Following Radical Prostatectomy. <i>Journal of Urology</i> , 2008, 180, 2459-2462.	0.4	8
112	Inguinal Hernias in Men Undergoing Open Radical Retropubic Prostatectomy. <i>Urology</i> , 2007, 70, 961-964.	1.0	38
113	The Short-Term and Long-Term Effects of Radical Prostatectomy on Lower Urinary Tract Symptoms. <i>Journal of Urology</i> , 2007, 178, 2397-2401.	0.4	24
114	Time to Return to Work and Physical Activity Following Open Radical Retropubic Prostatectomy. <i>Journal of Urology</i> , 2006, 176, 1420-1423.	0.4	39
115	Postoperative Blood Loss Predicts the Development of Urinary Extravasation on Cystogram Following Radical Retropubic Prostatectomy. <i>Journal of Urology</i> , 2006, 175, 146-150.	0.4	21
116	S7 Prostatic Stem Cells : Location and Biological Properties. <i>Japanese Journal of Urology</i> , 2006, 97, 147.	0.1	0
117	ULTRASENSITIVE SERLIM PROSTATE SPECIFIC ANTIGEN NADIR ACCURATELY PREDICTS THE RISK OF EARLY RELAPSE AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 173, 777-780.	0.4	77
118	Outcomes for men younger than 50 years undergoing radical prostatectomy. <i>Urology</i> , 2005, 66, 141-146.	1.0	46
119	Open versus laparoscopic radical prostatectomy. <i>Reviews in Urology</i> , 2005, 7, 115-27.	0.9	18
120	Radical Prostatectomy: Status and Opportunities for Improving Outcomes. <i>Cancer Investigation</i> , 2004, 22, 435-444.	1.3	19
121	The Impact of Open Radical Retropubic Prostatectomy on Continence and Lower Urinary Tract Symptoms: A Prospective Assessment Using Validated Self-Administered Outcome Instruments. <i>Journal of Urology</i> , 2004, 171, 1216-1219.	0.4	176
122	Continence Following Radical Retropubic Prostatectomy Using Self-Reporting Instruments. <i>Journal of Urology</i> , 2004, 171, 1212-1215.	0.4	112
123	Role of intraoperative biopsies during radical retropubic prostatectomy. <i>Urology</i> , 2004, 63, 499-502.	1.0	49
124	IL-9 Incidence prevention and management of urinary incontinence following radical prostatectomy (RP). <i>Japanese Journal of Urology</i> , 2004, 95, 273-274.	0.1	0
125	Practical considerations in radical retropubic prostatectomy. <i>Urologic Clinics of North America</i> , 2003, 30, 363-368.	1.8	19
126	The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. <i>New England Journal of Medicine</i> , 2003, 349, 2387-2398.	27.0	1,780

#	ARTICLE	IF	CITATIONS
127	Contemporary evaluation of operative parameters and complications related to open radical retropubic prostatectomy. <i>Urology</i> , 2003, 62, 702-706.	1.0	87
128	The New York University Nerve Sparing Algorithm Decreases the Rate of Positive Surgical Margins Following Radical Retropubic Prostatectomy. <i>Journal of Urology</i> , 2003, 169, 2147-2152.	0.4	51
129	Followup Interval Prostate Biopsy 3 Years After Diagnosis of High Grade Prostatic Intraepithelial Neoplasia is Associated With High Likelihood of Prostate Cancer, Independent of Change in Prostate Specific Antigen Levels. <i>Journal of Urology</i> , 2002, 168, 1415-1418.	0.4	104
130	ANALYSIS OF APICAL SOFT TISSUE MARGINS DURING RADICAL RETROPUBLIC PROSTATECTOMY. <i>Journal of Urology</i> , 2001, 165, 1943-1949.	0.4	75
131	Early removal of urinary catheter after radical retropubic prostatectomy is both feasible and desirable. <i>Urology</i> , 2001, 58, 425-429.	1.0	119
132	RADICAL RETROPUBLIC PROSTATECTOMY. <i>Urologic Clinics of North America</i> , 2001, 28, 509-519.	1.8	45
133	INTRAOPERATIVE AND POSTOPERATIVE COMPLICATIONS OF RADICAL RETROPUBLIC PROSTATECTOMY IN A CONSECUTIVE SERIES OF 1,000 CASES. <i>Journal of Urology</i> , 2001, 166, 1729-1733.	0.4	281
134	Predicting continence following radical prostatectomy. <i>Current Urology Reports</i> , 2001, 2, 248-252.	2.2	9
135	Generation of active TGF- β by prostatic cell cocultures using novel basal and luminal prostatic epithelial cell lines. <i>Journal of Cellular Physiology</i> , 2000, 184, 70-79.	4.1	31
136	Transforming growth factor- β is an autocrine mitogen for a novel androgen-responsive murine prostatic smooth muscle cell line, PSMC1. <i>Journal of Cellular Physiology</i> , 2000, 185, 416-424.	4.1	24
137	THE MECHANISM OF ADVERSE EVENTS ASSOCIATED WITH TERAZOSIN: AN ANALYSIS OF THE VETERANS AFFAIRS COOPERATIVE STUDY. <i>Journal of Urology</i> , 2000, 163, 1134-1137.	0.4	57
138	THE ROLE OF PREOPERATIVE EPOETIN ALFA IN MEN UNDERGOING RADICAL RETROPUBLIC PROSTATECTOMY. <i>Journal of Urology</i> , 2000, 163, 829-833.	0.4	39
139	Transforming growth factor- β 2 is an autocrine mitogen for a novel androgen-responsive murine prostatic smooth muscle cell line, PSMC1. <i>Journal of Cellular Physiology</i> , 2000, 185, 416-424.	4.1	1
140	Mitogenic activation of human prostate-derived fibromuscular stromal cells by bradykinin. <i>British Journal of Pharmacology</i> , 1999, 127, 220-226.	5.4	16
141	Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359. , 1999, 39, 234-239.		40
142	RADICAL RETROPUBLIC PROSTATECTOMY REDUCES SYMPTOM SCORES AND IMPROVES QUALITY OF LIFE IN MEN WITH MODERATE AND SEVERE LOWER URINARY TRACT SYMPTOMS. <i>Journal of Urology</i> , 1999, 161, 1185-1188.	0.4	70
143	LOCALIZATION AND EXPRESSION OF THE alpha 1A-1 , alpha 1B AND alpha 1D-ADRENOCEPTORS IN HYPERPLASTIC AND NON-HYPERPLASTIC HUMAN PROSTATE. <i>Journal of Urology</i> , 1999, 161, 635-640.	0.4	96
144	DOES SITE SPECIFIC LABELING OF SEXTANT BIOPSY CORES PREDICT THE SITE OF EXTRACAPSULAR EXTENSION IN RADICAL PROSTATECTOMY SURGICAL SPECIMEN?. <i>Journal of Urology</i> , 1999, 162, 1352-1357.	0.4	55

#	ARTICLE	IF	CITATIONS
145	Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359. Prostate, 1999, 39, 234-239.	2.3	3
146	Endothelin-1 production and agonist activities in cultured prostate-derived cells: Implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia. , 1998, 34, 241-250.		46
147	THE IMPACT OF MEDICAL THERAPY ON BOTHER DUE TO SYMPTOMS, QUALITY OF LIFE AND GLOBAL OUTCOME, AND FACTORS PREDICTING RESPONSE. Journal of Urology, 1998, 160, 1358-1367.	0.4	127
148	ALTERED SMOOTH MUSCLE DEVELOPMENT AND INNERVATION IN THE LOWER GENITOURINARY AND GASTROINTESTINAL TRACT OF THE MALE HUMAN FETUS WITH MYELOMENINGOCELE. Journal of Urology, 1998, 160, 1047-1053.	0.4	33
149	THE ROLE OF BLADDER NECK BIOPSY IN MEN UNDERGOING RADICAL RETROPUBIC PROSTATECTOMY WITH PRESERVATION OF THE BLADDER NECK. Journal of Urology, 1998, 160, 2435-2439.	0.4	38
150	Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic Hyperplasia. Urology, 1998, 51, 892-900.	1.0	349
151	Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial. Urology, 1998, 51, 901-906.	1.0	160
152	TWO CONSECUTIVE SETS OF TRANSRECTAL ULTRASOUND GUIDED SEXTANT BIOPSIES OF THE PROSTATE FOR THE DETECTION OF PROSTATE CANCER. Journal of Urology, 1998, 159, 471-476.	0.4	352
153	Evaluation of the Effect of Endothelin-1 and Characterization of the Selective Endothelin A Receptor Antagonist PD155080 in the Prostate. Journal of Urology, 1997, 158, 253-257.	0.4	22
154	Endothelins in Canine Genitourinary Tissues. Journal of Urology, 1997, 157, 1044-1048.	0.4	18
155	Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology, 1997, 49, 476-480.	1.0	39
156	Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy. Urology, 1997, 50, 727-732.	1.0	58
157	Doxazosin for Benign Prostatic Hyperplasia: Long-term Efficacy and Safety in Hypertensive and Normotensive Patients. Journal of Urology, 1997, 157, 525-530.	0.4	115
158	Morphometric analysis of pediatric and nonhyperplastic prostate glands: Evidence that BPH is not a unique stromal process. , 1997, 33, 177-182.		30
159	Morphometric analysis of pediatric and nonhyperplastic prostate glands: Evidence that BPH is not a unique stromal process. Prostate, 1997, 33, 177-182.	2.3	2
160	The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia. New England Journal of Medicine, 1996, 335, 533-540.	27.0	784
161	Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology, 1995, 45, 406-413.	1.0	151
162	Editorial: Benign Prostatic Hyperplasia. Journal of Urology, 1995, 153, 1540-1542.	0.4	7

#	ARTICLE	IF	CITATIONS
163	Localization of the alpha 1A-Adrenoceptor in the Human Prostate. Journal of Urology, 1995, 154, 2096-2099.	0.4	50
164	Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?. Journal of Urology, 1995, 154, 1770-1774.	0.4	446
165	Detection of prostate cancer in males with prostatism. Prostate, 1994, 25, 132-140.	2.3	15
166	Binding and Functional Properties of Alpha 1 Adrenoceptors in Different Regions of the Human Prostate. Journal of Urology, 1993, 150, 253-256.	0.4	26
167	Alpha 1 Adrenoceptor Subtypes in the Human Prostate. Journal of Urology, 1993, 149, 640-642.	0.4	86
168	Characterization and Localization of Prostatic Alpha 1 Adrenoceptors Using Radioligand Receptor Binding on Slide-Mounted Tissue Section. Journal of Urology, 1993, 150, 2002-2006.	0.4	83
169	The Effect of Obstruction on the Developing Bladder. Journal of Urology, 1992, 148, 491-496.	0.4	119
170	A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia. Journal of Urology, 1992, 148, 1467-1474.	0.4	324
171	The Safety, Efficacy and Compliance of Terazosin Therapy for Benign Prostatic Hyperplasia. Journal of Urology, 1992, 147, 1554-1557.	0.4	46
172	Quantitative Morphometry of the Adult Human Bladder. Journal of Urology, 1992, 148, 414-417.	0.4	111
173	Quantifying the Smooth Muscle Content of the Prostate Using Double-Immunoenzymatic Staining and Color Assisted Image Analysis. Journal of Urology, 1992, 147, 1167-1170.	0.4	139
174	The Relative Proportion of Stromal and Epithelial Hyperplasia is Related to the Development of Symptomatic Benign Prostate Hyperplasia. Journal of Urology, 1992, 147, 1293-1297.	0.4	274
175	The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. Prostate, 1992, 20, 89-95.	2.3	27
176	α 1-Adrenoceptor properties of terazosin HCl and its enantiomers in the human prostate and canine brain. Prostate, 1992, 20, 159-165.	2.3	7
177	Anti-desmin vs. anti-actin for quantifying the area density of prostate smooth muscle. Prostate, 1992, 20, 259-267.	2.3	64
178	The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate, 1992, 21, 297-307.	2.3	160
179	The efficacy and safety of terazosin for the treatment of symptomatic BPH. Prostate, 1991, 18, 345-355.	2.3	50
180	Characterization of 1,4, Dihydropyridine Calcium Channel Binding Sites in the Human Prostate. Journal of Urology, 1990, 144, 1539-1542.	0.4	3

#	ARTICLE	IF	CITATIONS
181	This Month in Investigative Urology: Alpha Adrenergic Innervation of the Prostate: Insights into Pharmacotherapy of BPH. Journal of Urology, 1990, 143, 590-591.	0.4	16
182	The Efficacy of Transurethral Resection of the Prostate in Men with Moderate Symptoms of Prostatism. Journal of Urology, 1990, 143, 533-537.	0.4	196
183	Binding and functional properties of doxazosin in the human prostate adenoma and canine brain. Prostate, 1990, 16, 29-38.	2.3	7
184	Nonoperative Management of Benign Prostatic Hyperplasia. Journal of Urology, 1989, 141, 1283-1289.	0.4	169
185	The role of radical prostatectomy in the management of prostatic cancer. Cancer, 1987, 60, 526-537.	4.1	124
186	Alpha 2 Adrenergic Receptors in Hyperplastic Human Prostate: Identification and Characterization Using [3 H] Rauwolscine. Journal of Urology, 1986, 135, 1038-1042.	0.4	64
187	Down Regulation of the Muscarinic Cholinergic Receptor of the Rat Prostate Following Castration. Journal of Urology, 1985, 134, 179-182.	0.4	32
188	Muscarinic Cholinergic Receptors in Bladder Exstrophy: Insights Into Surgical Management. Journal of Urology, 1985, 134, 308-310.	0.4	38
189	Precise Localization of the Autonomic Nerves From the pelvic Plexus to the Corpora Caverosa: a Detailed Anatomical Study of the Adult Male Pelvis. Journal of Urology, 1985, 133, 207-212.	0.4	430
190	Characterization of Alpha1Adrenergic Receptors in Human Benign Prostatic Hyperplasia. Journal of Urology, 1984, 132, 1226-1229.	0.4	155
191	Urethral Reconstruction in Boys with Classical Bladder Exstrophy. Journal of Urology, 1984, 131, 512-515.	0.4	39
192	Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations. Prostate, 1983, 4, 473-485.	2.3	974
193	Primary Bladder Closure and Bladder Neck Reconstruction in Classical Bladder Exstrophy. Journal of Urology, 1983, 130, 1142-1145.	0.4	92
194	Nephrogenic Adenoma: Clinical Features and Therapeutic Considerations. Journal of Urology, 1981, 126, 824-826.	0.4	56
195	Idiopathic Retroperitoneal Fibrosis. Journal of Urology, 1979, 122, 1-6.	0.4	232
196	A Prospective Pilot Study Investigating Performance of 18F-Fluciclovine PET Imaging for Detection of Prostate Cancer 2 Years Following Primary Partial Gland Cryoablation. Nuclear Medicine and Molecular Imaging, 0, , .	1.0	2